Testing a sustainable source of Taxol for the treatment of RUNX cancers using Caenorhabditis elegans

  • David van de Klashorst HAN University of Applied sciences
  • Samantha Hughes HAN University of Applied sciences

Abstract

RUNX proteins, master regulators of development, are frequently dysregulated in cancers, particularly leukaemia and breast cancer. A common drug for RUNX cancers, Paclitaxel, is derived from the bark of the Taxus plant. We tested compounds derived from leaves and needles of Taxus as a sustainable source of compounds to treat RUNX cancers. We accessed the effectiveness of Paclitaxel, Cephalomannine and 10-Deacetylbacatin III (10-DAB), in a Caenorhabditis elegans RUNX cancer model. Our results show Taxol derivatives have nuanced potency, affect development and fertility as well as reduce hyperproliferation. This research
paves the way for further C. elegans based research using Taxol compounds against RUNX.

How to Cite
VAN DE KLASHORST, David; HUGHES, Samantha. Testing a sustainable source of Taxol for the treatment of RUNX cancers using Caenorhabditis elegans. Student Undergraduate Research E-journal!, [S.l.], v. 4, nov. 2018. ISSN 2468-0443. Available at: <https://journals.library.tudelft.nl/index.php/sure/article/view/2812>. Date accessed: 14 dec. 2018. doi: https://doi.org/10.25609/sure.v4.2812.
Published
2018-11-09